接上期

线粒体乌头酸酶（Aco2）的生化脆弱性、氧化失活与营养干预策略：深度学术综述 2 

6. 分级证据总结与未来方向

6.1 证据等级汇总

6.2 关键未解决问题

1. ACO2失活-再激活的体内动力学： 在生理和病理条件下，ACO2在活性[4Fe-4S]²⁺和非活性[3Fe-4S]⁺形式之间的动态平衡尚需在活体水平定量表征。

2. MR对ACO2的直接效应： 虽然MR降低mtROS和增强GSH合成的机制强烈提示对ACO2的保护，但需直接测量MR条件下ACO2活性和[4Fe-4S]簇完整性的实验验证。

3. 铁螯合剂的治疗窗口： DFP的双重效应（保护vs抑制ACO2）需要在不同病理模型中精确定量其治疗窗口，可能需要开发真正的线粒体靶向螯合剂。

4. mitohormesis与ACO2保护的治疗矛盾： ACO2的可逆失活是mitohormetic信号（柠檬酸输出→组蛋白乙酰化→适应性基因表达）的触发器，但持续失活导致ISR激活和病理后果。如何在保护ACO2的同时保留其信号功能，是营养干预策略设计中的核心挑战。

5. 组织特异性差异： ACO2在不同组织中的表达水平、铁稳态和氧化还原环境差异显著（如肾脏生理性摄取循环柠檬酸、前列腺Zn²⁺介导的ACO2抑制），营养干预策略需考虑组织特异性。

6. 硒-铁交互作用： 硒通过硒蛋白系统间接保护ACO2，但硒代谢本身可产生超氧化物（亚硒酸盐被GSH还原时），可能损伤Fe-S簇——这一悖论需在不同硒剂量和形式下系统评估。

6.3 未来研究方向

• 开发线粒体靶向的ACO2活性探针，实现体内实时监测

• 利用同位素示踪和代谢组学系统表征ACO2失活-再激活对TCA循环通量的影响

• 在蛋氨酸限制模型中直接测量ACO2活性和[4Fe-4S]簇状态

• 开发具有精确剂量控制的新型线粒体靶向铁螯合剂

• 系统评估不同形式和剂量的硒对ACO2/Fe-S簇的双相效应

• 探索ACO2失活-柠檬酸输出-组蛋白乙酰化轴在不同疾病模型中的治疗潜力

参考文献

1. Padalko VI. Mitochondrial      Aconitase and Its Contribution to the Pathogenesis of Neurodegenerative      Diseases. Int J Mol Sci. 2024;25(18):9950. 

2. Castro L, Tortora V,      Mansilla S, Radi R. Aconitases: Non-redox Iron–Sulfur Proteins Sensitive      to Reactive Species. Acc Chem Res. 2019;52(9):2609–2619. 

3. Lushchak OV, Piroddi M,      Galli F, Lushchak VI. Aconitase post-translational modification as a key      in linkage between Krebs cycle, ROS metabolism and iron homeostasis. Free      Radic Res. 2014;48(1):26–37. 

4. Imlay JA. Iron-sulphur      clusters and the problem with oxygen. Mol Microbiol. 2006;59(4):1073–1082.      

5. Vásquez-Vivar J,      Kalyanaraman B, Kennedy MC. Mitochondrial aconitase is a source of      hydroxyl radical. J Biol Chem. 2000;275(19):14064–14069.

6. Gardner PR.      Superoxide-driven aconitase FE-S center cycling. Biosci Rep.      1997;17(1):33–42. 

7. Bulteau AL, Ikeda-Saito      M, Szweda LI. Redox-dependent modulation of aconitase activity in intact      mitochondria. Biochemistry. 2003;42(50):14846–14855. 

8. Castro L, Rodriguez M,      Radi R. Aconitase is readily inactivated by peroxynitrite, but not by its      precursor, nitric oxide. J Biol Chem. 1994;269(47):29409–29415. 

9. Tortora V, Quijano C,      Freeman B, Radi R, Castro L. Mitochondrial aconitase reaction with nitric      oxide, S-nitrosoglutathione, and peroxynitrite: mechanisms and relative      contributions to aconitase inactivation. Free Radic Biol Med.      2007;42(7):1075–1088. 

10. Han D, Canali R, Garcia      J, Aguilera R, Özer NK, Cadenas E. Sites and mechanisms of aconitase      inactivation by peroxynitrite: modulation by citrate and glutathione.      Biochemistry. 2005;44(34):11986–11996.

11. Xie A, Brunner JS,      Chakraborty S, et al. Citrate clearance is a major function of aconitase 2      in the canonical TCA cycle. Cell. 2026;189(5). 

12. Donnelly MP, Mangalhara      KC, Liu Y, et al. Mitochondrial superoxide–induced mitohormesis is      mediated by citrate and cardioprotective. Sci Adv.      2026;12(36):eaef8132. 

13. Palmeira CM, Teodoro JS,      Amorim JA, Steegborn C, Sinclair DA, Rolo AP. Mitohormesis and metabolic      health: The interplay between ROS, cAMP, and sirtuins. Free Radic Biol      Med. 2019;141:483–491. 

14. Ristow M, Schmeisser K.      Mitohormesis: Promoting Health and Lifespan by Increased Levels of      Reactive Oxygen Species (ROS). Dose Response. 2014;12(2):288–341. 

15. Cox CS, McKay SE,      Holmbeck MA, et al. Mitohormesis in Mice via Sustained Basal Activation of      Mitochondrial and Antioxidant Signaling. Cell Metab.      2018;28(5):776–789. 

16. Vaubel RA, Isaya G.      Iron-sulfur cluster synthesis, iron homeostasis and oxidative stress in      Friedreich ataxia. Mol Cell Neurosci. 2012;55:50–61. 

17. Bulteau AL, O'Neill HA,      Kennedy MC, Ikeda-Saito M, Isaya G, Szweda LI. Frataxin acts as an iron      chaperone protein to modulate mitochondrial aconitase activity. Science.      2004;305(5681):242–246.

18. Parent A, Eldridge M,      Santi G, et al. Mammalian frataxin directly enhances sulfur transfer of      NFS1 persulfide to both ISCU and free thiols. Nat Commun.      2015;6:5686. 

19. Ast T, Meiser J, Song JD,      et al. Hypoxia Rescues Frataxin Loss by Restoring Iron Sulfur Cluster      Biogenesis. Cell. 2019;177(6):1507–1521. 

20. Das D, Nahmias C, Isaya      G, et al. Mechanism of frataxin "bypass" in human iron-sulfur      cluster biogenesis. J Biol Chem. 2019;294(23):9275–9290.

21. Weiler BD, Brück MC,      Kothe I, et al. Mitochondrial [4Fe-4S] protein assembly involves reductive      [2Fe-2S] cluster fusion on ISCA1–ISCA2 by electron flow from ferredoxin      FDX2. Proc Natl Acad Sci USA. 2020;117(34):20555–20565. 

22. Melber A, Na U, Vashisht      A, et al. Role of Nfu1 and Bol3 in iron-sulfur cluster transfer to      mitochondrial clients. eLife. 2016;5:e15991. 

23. Read AD, Bentley RE,      Archer SL, Dunham-Snary KJ. Mitochondrial iron–sulfur clusters: Structure,      function, and an emerging role in vascular biology. Redox Biol.      2021;47:102154.

24. Cheng Z, Yamamoto T,      Seller S, et al. Pulling back the mitochondria's iron curtain. EMBO J.      2025;44(5):e70189. 

25. Goncalves S, Paupe V,      Dassa EP, Rustin P. Deferiprone targets aconitase: implication for      Friedreich's ataxia treatment. BMC Neurol. 2008;8:20.

26. Kakhlon O, Manning H,      Breuer W, et al. Cell functions impaired by frataxin deficiency are      restored by drug-mediated iron relocation. Blood.      2008;112(12):5219–5227. 

27. Devos D, Moreau C,      Dujardin K, et al. Targeting chelatable iron as a therapeutic modality in      Parkinson's disease. Antioxid Redox Signal. 2014;21(2):195–210. 

28. Kelly CJ, Exline MC,      Ahmad A, et al. Iron status influences mitochondrial disease progression      in Ndufs4 knockout mice. eLife. 2023;12:e75825. 

29. Tesfay L, Bhatti I, Deng      Z, et al. Inhibition of prostate cancer proliferation by Deferiprone. PLoS      One. 2017;12(6):e0179286. 

30. Kontoghiorghes GJ,      Kolnagou A, Kontoghiorghes CN. New Iron Metabolic Pathways and Chelation      Targeting Strategies Affecting Infections and Cancer. Int J Mol Sci.      2022;23(22):13990. 

31. Sanz A, Caro P, Ayala V,      et al. Methionine restriction decreases mitochondrial oxygen radical      generation and leak as well as oxidative damage to mitochondrial DNA and      proteins. FASEB J. 2006;20(8):1064–1073. 

32. Lee BC, Kaya A, Ma S, et      al. Effect of Methionine Restriction on Aging: Its Relationship to      Oxidative Stress. Oxid Med Cell Longev. 2021;2021:5583219. 

33. Kitada M, Ogura Y, Monno      I, Koya D. Methionine restriction - Association with redox homeostasis and      aging. Front Aging. 2022;3:908581. 

34. Hine C, Harputlugil E,      Zhang Y, et al. Endogenous hydrogen sulfide production is essential for      dietary restriction benefits. Cell. 2015;160(1-2):132–144.

35. Singh A, Kukreti R,      Kukreti S. NAC, NAC, Knockin' on Heaven's door. Antioxidants.      2022;11(10):1964.

36. Ezeriņa D, Takano Y,      Hanaoka K, Urano Y, Dick TP. N-acetyl cysteine functions as a fast-acting      antioxidant by triggering intracellular H2S and sulfane sulfur production.      Cell Chem Biol. 2018;25(4):447–459.

37. Conrad M, Angeli JP.      Selenium and iron, two elemental rivals in the ferroptotic death process.      Oncotarget. 2018;9(40):26283–26284. 

38. Angeli JP, Shahnia F,      Conrad M. Ferroptosis: molecular mechanisms and health implications. Sci      China Life Sci. 2020;63(11):1680–1697. 

39. Krewing M, Călinescu TO,      Lucas IS, et al. Iron-sulfur cluster proteins present the weak spot in      non-enzymatic protein damage by plasma-generated species. Redox Biol.      2025;55:103548. 

40. Cantu D, Schaack J, Patel      M. Oxidative Inactivation of Mitochondrial Aconitase Results in Iron and      H2O2 Amplification: Neurotoxicity in Dopaminergic Midbrain Neurons.      Neurochem Int. 2009;55(1-3):42–50. 

41. PLoS Genetics. Aconitase      Causes Iron Toxicity in Drosophila pink1 Mutants. 2013.

42. Mansilla S, Castro L,      Tortora V, Radi R. Redox sensitive human mitochondrial aconitase and its      implications in cardiovascular and neurodegenerative diseases. Free Radic      Biol Med. 2023;197:95–107.

43. GSH redox decisions in      cell survival and death. Vita. 2026;6(6):e0040.

44. Park ES, Yoo YS, Jeong      SW, Kim HJ. Role of GSH and iron-sulfur glutaredoxins in iron metabolism –      Review. BMB Rep. 2024;57(1):25–34.

45. Tuning the Fire:      Context-Dependent Mitochondrial ROS Signaling in Health and Disease.      Antioxidants. 2026;15(6):1402. 

46. Cilibrizzi A, Quinn JT,      Darbar R, et al. The synthesis and properties of mitochondrial targeted      iron chelators. Molecules. 2022;27(8):2446. 

47. Campanella A, et al.      First Evidence of a Protective Effect of Plant Bioactive Compounds against      H2O2-Induced Aconitase Damage in Durum Wheat Mitochondria. Int J Mol Sci.      2020;21(24):9421. 

48. Varghese S, Tang Y, Imlay      JA. Contrasting Sensitivities of Escherichia coli Aconitases A and B to      Oxidation and Iron Depletion. J Bacteriol. 2003;185(1):221–230. 

49. Duarte-Silva T,      Silva-Ferreira J, et al. Role of aconitase in plant stress response and      signaling. Physiol Plant. 2024;176(3):e70128. 

50. Peroxynitrite, a Stealthy      Biological Oxidant. 2013. 

51. Structure of activated      aconitase: formation of the [4Fe-4S] cluster. 2013. 

52. Distinct Roles of CyaY      and YggX Proteins in Biosynthesis and Repair of Iron-Sulfur Clusters.      2014. 

53. Napoli E, et al.      Frataxin, iron-sulfur clusters, heme, ROS, and aging. Antioxid Redox      Signal. 2006;8(3-4):506–516. 

54. CLPX acquires an      iron-sulfur cluster to sustain mitochondrial proteostasis. Nat Commun.      2026. 

55. Superoxide generated from      glutathione-mediated reduction of selenite damages iron-sulfur cluster of      ferredoxin. 2016. 

56. Iron–sulfur cluster      biosynthesis and trafficking – impact on human disease conditions.      Metallomics. 2018;10(1):9–21. 

57. Iron-sulfur cluster      biogenesis and human disease. 2008. 

58. Biogenesis of Iron–Sulfur      Clusters and Their Role in DNA Metabolism. 2021. 

59. Mitochondrial frataxin      interacts with ISD11 of the NFS1/ISCU complex. Hum Mol Genet.      2007;16(8):929–941. 

60. Nitric Oxide and      Peroxynitrite in Health and Disease. 2008. 

61. The Resistance of      Electron Transport Chain Fe-S Clusters to Oxidative/Nitrosative Damage.      2008. 

62. EPR investigation of the      products of the reaction of cytosolic and mitochondrial aconitases with      nitric oxide. 1997.

63. Nitric oxide and      peroxynitrite-dependent aconitase inactivation in mammalian fibroblasts. 1998. 

64. Advanced Biomedicine. Autophagy and its role in      metabolic regulation. 2023. 

65. Mitochondrial iron handling and lipid peroxidation      as drivers of ferroptosis. Int J Mol Sci. 2026;27(5):2232.

66. When Pathways Converge: Iron, Lipid Peroxidation,      and α-synuclein. J Neurochem. 2026. 

67. Generation of reactive oxygen species by      hydroxypyridone compound/iron complexes. 2020. 

68. The significance, trafficking and determination of      labile iron. 2018. 

69. Chemical, Biological and Medical Controversies      Surrounding the Fenton Reaction. 2003.

70. Emerging antioxidant therapies in Friedreich's      ataxia. Front Pharmacol. 2024;15:1359618. 

71. Targeting mitochondria for the treatment of      neurodegenerative diseases. Front Neurosci. 2026;20:1835506. 

72. Effect of iron chelators on labile iron and      oxidative status. 2009. 

73. Iron redistribution as a therapeutic strategy.      2010. 

74. Methionine restriction delays senescence and      suppresses SASP. 2019.

75. Regulation of longevity and oxidative stress by      nutritional interventions. 2013. 

76. Methionine restriction and lifespan control.      2016. 

77. Dietary restriction, mitochondrial function and      aging. 2015. 

78. The Potential Implications of Hydrogen Sulfide in      Aging. 2022. 

79. Mitohormesis in exercise training. 2016. 

80. Mitohormesis. PMC. 2014.

注释：本文由靳海宁博士和徐斌博士完成，AI提供辅助。请给予批评和指导性意见！

支持单位：